These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 15449549)

  • 1. [Effects of acute octreotide infusion on renal function in patients with cirrhosis and portal hypertension].
    Silva G; Segovia R; Backhouse C; Palma M; Márquez S; Iturriaga H
    Rev Med Chil; 2004 Feb; 132(2):144-50. PubMed ID: 15449549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of a long-acting formulation of octreotide on renal function and renal sodium handling in cirrhotic patients with portal hypertension: a randomized, double-blind, controlled trial.
    Ottesen LH; Aagaard NK; Kiszka-Kanowitz M; Rehling M; Henriksen JH; Pedersen EB; Flyvbjerg A; Bendtsen F
    Hepatology; 2001 Sep; 34(3):471-7. PubMed ID: 11526531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 48-hour hemodynamic effects of octreotide on postprandial splanchnic hyperemia in patients with liver cirrhosis and portal hypertension: double-blind, placebo-controlled study.
    Ludwig D; Schädel S; Brüning A; Schiefer B; Stange EF
    Dig Dis Sci; 2000 May; 45(5):1019-27. PubMed ID: 10795771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The organ extraction and splanchnic haemodynamic effects of octreotide in cirrhotic patients.
    Ottesen LH; Flyvbjerg A; Møller S; Bendtsen F
    Aliment Pharmacol Ther; 1998 Jul; 12(7):657-65. PubMed ID: 9701530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension.
    Escorsell A; Bandi JC; Andreu V; Moitinho E; García-Pagán JC; Bosch J; Rodés J
    Gastroenterology; 2001 Jan; 120(1):161-9. PubMed ID: 11208725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison.
    Baik SK; Jeong PH; Ji SW; Yoo BS; Kim HS; Lee DK; Kwon SO; Kim YJ; Park JW; Chang SJ; Lee SS
    Am J Gastroenterol; 2005 Mar; 100(3):631-5. PubMed ID: 15743362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Octreotide in liver cirrhosis: a salvage for variceal bleeding can be a gunshot for kidneys.
    Güney Duman D; Tüney D; Bilsel S; Benli F; Karan S; Avsar E; Ozdogan O; Tözün N
    Liver Int; 2005 Jun; 25(3):527-35. PubMed ID: 15910489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites.
    Angeli P; Volpin R; Piovan D; Bortoluzzi A; Craighero R; Bottaro S; Finucci GF; Casiglia E; Sticca A; De Toni R; Pavan L; Gatta A
    Hepatology; 1998 Oct; 28(4):937-43. PubMed ID: 9755229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Splanchnic hemodynamic effects of somatostatin and octreotide in cirrhotic patients. A Doppler ultrasonographic study].
    Fernández Pérez FJ; Jiménez Sáenz M; García Montes JM; Rebollo Bernárdez J; Herrerías Gutiérrez JM
    Rev Esp Enferm Dig; 2008 Sep; 100(9):552-9. PubMed ID: 19025306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: long-term hemodynamic and renal effects.
    Morillas RM; Planas R; Cabré E; Galán A; Quer JC; Feu F; García Pagán JC; Bosch J; Gassull MA
    Hepatology; 1994 Dec; 20(6):1502-8. PubMed ID: 7982651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal effects of treatment with diuretics, octreotide or both, in non-azotemic cirrhotic patients with ascites.
    Kalambokis G; Economou M; Fotopoulos A; Bokharhii JA; Katsaraki A; Tsianos EV
    Nephrol Dial Transplant; 2005 Aug; 20(8):1623-9. PubMed ID: 15886218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Octreotide enhances portal pressure reduction induced by propranolol in cirrhosis: a randomized, controlled trial.
    Vorobioff JD; Ferretti SE; Zangroniz P; Gamen M; Picabea E; Bessone FO; Reggiardo V; Diez AR; Tanno M; Cuesta C; Tanno HE
    Am J Gastroenterol; 2007 Oct; 102(10):2206-13. PubMed ID: 17608776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of nadolol treatment on renal and hepatic hemodynamics and function in cirrhotic patients with portal hypertension.
    Gatta A; Sacerdoti D; Merkel C; Milani L; Battaglia G; Zuin R
    Am Heart J; 1984 Oct; 108(4 Pt 2):1167-72. PubMed ID: 6148880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of two different dosages of octreotide on portal pressure and hepatic hemodynamics in cirrhotic portal hypertensive patients after portal-azygous devascularization and splenectomy].
    Lu SC; Meng FK; Ding HG; Zhang JG; Ding L; Wang SZ
    Zhonghua Nei Ke Za Zhi; 2007 Apr; 46(4):290-3. PubMed ID: 17637266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of glucagon improves splanchnic hyporesponse to terlipressin in cirrhotic rats with blood retention in the gastric lumen.
    Yang YY; Lin HC; Huang YT; Hou MC; Lee FY; Chang FY; Lee SD
    J Hepatol; 2005 May; 42(5):652-8. PubMed ID: 15826713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of treatment with octreotide, diuretics, or both on portal hemodynamics in nonazotemic cirrhotic patients with ascites.
    Kalambokis G; Economou M; Kosta P; Papadimitriou K; Tsianos EV
    J Clin Gastroenterol; 2006 Apr; 40(4):342-6. PubMed ID: 16633107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study.
    Spahr L; Giostra E; Frossard JL; Morard I; Mentha G; Hadengue A
    Am J Gastroenterol; 2007 Jul; 102(7):1397-405. PubMed ID: 17488248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Octreotide bolus injection and azygos blood flow in patients with cirrhosis: is the effect really predictable?
    Spahr L; Giostra E; Mentha G; Hadengue A
    J Clin Gastroenterol; 2010 Oct; 44(9):e206-9. PubMed ID: 19996986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood digestion-induced splanchnic hyperemia and portal blood flow in portal hypertensive rats and the role of octreotide.
    Kotzampassi K; Eleftheriadis E
    J Gastroenterol; 1998 Oct; 33(5):678-83. PubMed ID: 9773932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized controlled trial comparing octreotide and vasopressin in the control of acute esophageal variceal bleeding.
    Hwang SJ; Lin HC; Chang CF; Lee FY; Lu CW; Hsia HC; Wang SS; Lee SD; Tsai YT; Lo KJ
    J Hepatol; 1992 Nov; 16(3):320-5. PubMed ID: 1487608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.